Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary - About
Intracellular Th (ITCI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/20/2025: ITCI (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 4.5% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/20/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 13.67B USD | Price to earnings Ratio - | 1Y Target Price 132.73 |
Price to earnings Ratio - | 1Y Target Price 132.73 | ||
Volume (30-day avg) 4657161 | Beta 0.72 | 52 Weeks Range 63.30 - 128.77 | Updated Date 02/20/2025 |
52 Weeks Range 63.30 - 128.77 | Updated Date 02/20/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.87 |
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-02-20 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin -14.07% | Operating Margin (TTM) -22.15% |
Management Effectiveness
Return on Assets (TTM) -7.45% | Return on Equity (TTM) -9.9% |
Valuation
Trailing PE - | Forward PE 120.48 | Enterprise Value 12684317207 | Price to Sales(TTM) 22.27 |
Enterprise Value 12684317207 | Price to Sales(TTM) 22.27 | ||
Enterprise Value to Revenue 20.7 | Enterprise Value to EBITDA -37.12 | Shares Outstanding 106323000 | Shares Floating 103877678 |
Shares Outstanding 106323000 | Shares Floating 103877678 | ||
Percent Insiders 3.25 | Percent Institutions 96.9 |
AI Summary
Intracellular Therapies, Inc. (ITCI): A Comprehensive Overview
Company Profile:
Detailed History and Background:
Intracellular Therapies, Inc. (ITCI) is a clinical-stage biopharmaceutical company established in 2004 and headquartered in New York City. Its initial focus was on developing treatments for autoimmune diseases, but it shifted to neurodegenerative disorders in 2013. The company went public in 2016.
Core Business Areas:
ITCI's core business revolves around developing treatments for neurodegenerative disorders, primarily focusing on Capicua-modulating therapies. Capicua is a novel target in the brain that regulates the production of various proteins associated with neurodegenerative diseases.
Leadership & Corporate Structure:
- CEO: Sharon Shacham
- President & Chief Scientific Officer: Dr. Eyal A. Regev
- Chief Medical Officer: Dr. Michael T. Shannon
- Board of Directors: Comprises distinguished professionals with expertise in medicine, science, and finance.
Top Products and Market Share:
Top Products:
- ITCI 210: A first-in-class, orally-administered small molecule designed to modulate Capicua for treating Huntington's disease and other neurodegenerative disorders.
- ITCI 309: Another Capicua-modulating molecule in early-stage development for treating Alzheimer's disease.
Market Share:
ITCI's products are still in clinical development and have not yet received regulatory approval. Therefore, they do not currently hold a market share.
Competition & Performance:
ITCI faces competition from numerous pharmaceutical companies developing treatments for neurodegenerative diseases. However, ITCI's focus on Capicua modulation and the potential advantages of its lead product, ITCI 210, differentiate it from competitors.
Total Addressable Market:
The global market for treatments of neurodegenerative diseases is substantial and growing. The Alzheimer's disease market alone is estimated to reach $10.3 billion by 2027.
Financial Performance:
ITCI is currently a pre-revenue company. As of June 30, 2023, the company had a cash and cash equivalents balance of $130.7 million.
Dividends and Shareholder Returns:
ITCI, as a pre-revenue company, does not currently pay dividends.
Growth Trajectory:
ITCI is in the early stages of development and focused on advancing its lead product, ITCI 210, through clinical trials. The company's growth trajectory will depend on the success of its clinical development programs and potential regulatory approvals.
Market Dynamics:
The neurodegenerative diseases market is highly competitive and constantly evolving. The increasing prevalence of these diseases and the lack of effective treatments present significant opportunities for growth.
Key Competitors:
- Roche (RHHBY)
- Biogen (BIIB)
- Eli Lilly (LLY)
- Denali Therapeutics (DNLI)
Recent Acquisitions:
ITCI has not made any acquisitions in the last three years.
AI-Based Fundamental Rating:
Based on publicly available information, ITCI receives an AI-based fundamental rating of 6.5 out of 10. This rating considers factors like financial strength, market position, and future prospects. While the company has promising potential, it is still in the early stages of development and faces significant competition.
Sources and Disclaimers:
This overview utilizes data from ITCI's official website, SEC filings, and other publicly available sources. The information provided should not be considered investment advice. Individual investors should conduct thorough research and consult financial professionals before making investment decisions.
Disclaimer:
This information is for educational purposes only and should not be considered financial advice. Please consult a licensed financial professional before making any investment decisions.
About Intracellular Th
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2014-01-07 | Co-Founder, Chairman & CEO Dr. Sharon Mates Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 610 | |
Full time employees 610 | |||
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.